The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
171 - If a physician who was not able to attend a congress/confrence(e.g. ASH, ASCO, ADA) requests through medical information slides on company studies presented at the congress are we allowed to provide them?
-
The Health Canada policy document "The Distinction Between Advertising and Other Activities" does not consider responses to specific questions from a medical info department to be advertising. The request should be SPECIFIC and DOCUMENTED. Such a response would be exempt from PAAB preclearance review. We remind you that, while a company may promote the fact that it has a medical information service, it should not promote individual studies that are not consistent with the product's Terms of Market Authorization (TMA). If drugs are mentioned in an institutional message, even within study titles, PAAB preclearance review is required.
